Zespri Achieves a First for Fresh Produce with EU-Approved Health Claim for Green Kiwifruit
ANTWERP, Belgium, August 21, 2025--(BUSINESS WIRE)--Green kiwifruit has become the first fresh fruit ever to receive an authorised health claim from the European Commission, marking a breakthrough for kiwifruit marketer Zespri and the wider fresh produce industry.
The European Commission has officially approved the health claim that "consumption of green kiwifruit contributes to normal bowel function by increasing stool frequency" – based on a daily intake of two fresh green kiwifruit (Actinidia deliciosa var. Hayward) providing a minimum of 200g of flesh.
This authorisation is among only three health claims approved by the European Commission in the last five years, following a rigorous evaluation process in which only less than 1 out of 8 claims submitted receive approval.
Zespri CEO Jason Te Brake says, "This milestone is not only a first for Zespri but for the entire fresh produce industry. The EU Commission's recognition of green kiwifruit's role in digestive health reflects one of the ways we are helping people thrive through the goodness of kiwifruit. The approval not only validates Zespri's health and innovation programme, it also delivers tangible value to the industry and reflects the hard work of our green growers to produce nutritious, great-tasting kiwifruit."
Zespri fully funded the application process and majority of the key research submitted in the scientific substantiation, committing over 15 years to documenting the benefits of green kiwifruit. The approval follows the submission of a comprehensive scientific dossier in 2018 which included 18 human intervention studies, six of which ultimately were considered as a strong basis for proving the effect of green kiwifruit on intestinal function. The European Food Safety Authority (EFSA) delivered a positive scientific opinion in 2021, which has now culminated in the Commission's formal authorisation.
This landmark achievement demonstrates the critical value of investing in health and nutrition science -both to build trust in the fresh category and to unlock further growth and demand for green kiwifruit. In 2024/25, Zespri supplied a total of 220.9 million trays (ZespriTM Green, ZespriTM RubyRedTM and ZespriTM SunGoldTM Kiwifruit) to more than 50 markets.
Zespri Green kiwifruit is packed with essential nutrients including fiber, the beneficial effects on digestive health of which are well-documented in scientific research. The European Commission has now recognized the benefits of green kiwifruit for promoting good bowel habits, confirming the added value of this delicious fruit that many consumers already experience through daily consumption.
As European consumers become increasingly proactive about their health and seek naturally nutritious foods with proven benefits, Zespri's leadership sets a blueprint for fresh produce that science-led innovation delivers real value for consumers and the industry.
With this new authorisation, Zespri will begin integrating the health claim into its European communications, reaffirming its commitment to helping consumers make informed choices about their health.
IMAGERY
Imagery of Zespri Green Kiwifuit can be found in the following link
https://www.dropbox.com/scl/fo/jz98ececpohek5z28ok1f/AA6R9cZkQFu7oOvnqUL4ENI?rlkey=sz18pcfmh57kg0su9va3s5mie&st=sxttuz20&dl=0
LINKS
Official Journal of the European Union: https://eurlex.europa.eu/eli/reg_impl/2025/1560/oj
EFSA health claims page: https://www.efsa.europa.eu/en/topics/topic/health-claims
ABOUT ZESPRI
Zespri is 100 percent owned by current and former kiwifruit growers and has a global team of 900+ based in Mount Maunganui and throughout Asia, Europe and the Americas. Our purpose is to help people, communities and the environment thrive through the goodness of kiwifruit, and we work with 2,800 growers in New Zealand and 1,500 growers offshore to provide consumers with fresh, healthy and great-tasting Zespri Green, Zespri RubyRed and SunGold Kiwifruit. In 2024/25, we supplied 220.9 million trays (more than 795,000 tonnes) of kiwifruit to consumers in more than 50 markets, and recorded global operating revenue of NZ$5.14 billion. Zespri is committed to sustainability, with areas of improvement identified right through the supply chain including our pledge that by 2025 we will use 100 percent reusable, recyclable or compostable packaging, do more to help the environment, and work with our partners to be carbon positive by 2035.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250820737646/en/
Contacts
MEDIA CONTACTMaria BengtssonMaria@united-partners.com +34 711 016 382
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
22 minutes ago
- Medscape
New First-Line Option for Advanced Bladder Cancer
The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. More than 1200 people in England are expected to benefit each year. Clinical experts described the combination therapy as a "step change" in bladder cancer management. Until now, treatment options for this patient group have seen little meaningful progress since the 1980s. Enfortumab vedotin is an antibody-drug conjugate consisting of an antibody targeting Nectin-4, a protein highly expressed in urothelial carcinoma cells. After binding, it causes the cells to release monomethyl auristatin E, resulting in cell death. Pembrolizumab, its combination partner, is a PD-1 inhibitor. High Disease Burden Urothelial cancer accounts for around 90% of bladder cancers, affecting more than 18,000 people annually in England. Prognosis is poor, with only 10% of patients with stage 4 disease surviving for 5 years or more. Current standard treatments include platinum-based chemotherapy ( cisplatin or carboplatin with gemcitabine), followed by avelumab maintenance therapy if the cancer has not progressed. However, only about 12% of patients see improvement with chemotherapy, underscoring the need for better options. Patient experts described living with metastatic urothelial cancer as "intensely challenging and emotionally exhausting', affecting work, travel, and physical activity. Action Bladder Cancer UK called the announcement a 'very welcome, and significant, step forward for this hard-to-treat cancer'. Clinical Evidence The recommendation in final draft guidance was supported by results from the phase 3 EV-302 trial, which enrolled 886 adults with untreated, unresectable, locally advanced, or metastatic urothelial cancer. Participants were randomly assigned in a 1:1 ratio to receive either enfortumab vedotin–pembrolizumab or standard chemotherapy. Enfortumab vedotin–pembrolizumab nearly doubled the median time to disease progression or death to 12.5 months, compared with 6.3 months for chemotherapy. Median overall survival was also improved, at 33.8 months versus 15.9 months with chemotherapy. Helen Knight, director of medicines evaluation at NICE, said the drug combination is 'highly promising and effective,' adding that these clinical trial results highlight the 'tremendous difference' it could make to the length and quality of people's lives. Cost and NHS Access Enfortumab vedotin is listed at £578 per 20 mg vial or £867 per 30 mg vial. Pembrolizumab costs £2630 per 100 mg vial, excluding VAT. The drugs will be supplied through confidential commercial arrangements with the NHS. NICE's appraisal committee applied a severity modifier, reflecting the high disease burden, and concluded that the therapy met acceptable cost-effectiveness thresholds. The treatment will be available immediately across the NHS in England, with funding required within 90 days of final publication of the guidance.
Medscape
an hour ago
- Medscape
Safety Watchdog Flags Ongoing Maternity Risks
The Health Services Safety Investigations Body (HSSIB) has released a preliminary report on maternity and neonatal safety in England. The exploratory review, carried out in spring 2025, highlighted concerns across the entire maternity and neonatal care pathway despite years of initiatives aimed at improvement. The review comes after a series of high-profile scandals, including at Shrewsbury and Telford Hospital NHS Trust and Nottingham University Hospitals NHS Trust. The Shrewsbury inquiry, led by senior midwife Donna Ockenden, found that approximately 201 babies and nine mothers might have survived if they had received better care. The Nottingham review — also led by Ockenden — remains ongoing. Safety Concerns and Baby Deaths The HSSIB's latest report indicates that safety concerns persist. Between October 2023 and June 2025, the board received 35 reports of safety concerns in maternity or neonatal services. These accounted for about 10% of all safety concerns received during that period. All cases involved "very serious harm", including 10 baby deaths. Sixteen incidents occurred during labour, and 12 during the neonatal period. Most reports came from women or family members, although some were submitted by healthcare staff. Full Investigation Paused The board had begun a scoping exercise to assess the need for a full investigation. However, the work was paused in June after the Secretary of State for Health and Social Care announced a national investigation into maternity and neonatal services, due to report in December 2025. Health Secretary Wes Streeting said that multiple reviews into local trusts had found "similar failings in compassionate care" after maternity service failures "that should never have happened". He acknowledged "systemic" failings dating back more than 15 years and said families had been "gaslit" in their search for answers about their babies' deaths. Although pausing its work, the HSSIB published its exploratory findings to support the national investigation. These were based on the 35 recent safety reports, meetings with 17 stakeholders, and a 2021 report by its precursor organisation, the Healthcare Safety Investigation Branch. 'Compounded Harms' to Families The report identified 11 key themes. Progress had been made in maternity and neonatal outcomes, staffing levels, and governance, but disparities in care and outcomes persisted, partly due to health inequalities. The HSSIB found that maternity and neonatal systems were overly complex, with inconsistent collaboration and poor information sharing. Local governance often operated in isolation, and services struggled to identify and respond to clinical risks or to learn from the harms that happened to women and babies during pregnancy, labour, and birth. "Patients experience compounded harm due to issues within the wider healthcare system," the report concluded. It highlighted that local investigations, complaints processes, and legal proceedings such as inquests often caused additional harm. "Staff and trusts can lose sight of compassion during this process," it said. Four Areas for Further Review The HSSIB recommended four areas for potential further investigation: National structures responsible for providing direction and oversight for maternity services. Local governance and its relationship to national bodies. Standards and approaches of local investigations when things go wrong. Education, training, and professional standards for clinicians. Staff Experience Cumulative Stress The report said that maternity and neonatal staff also experienced cumulative stress and harm. It raised concerns about the standards set in undergraduate and postgraduate education, and whether these could be met in practice, noting that too many recommendations were being made, with limited implementation. The HSSIB warned that multiple, high-profile maternity investigations and inquiries had eroded public confidence in maternity services. Some women were avoiding hospitals that had been the focus of national investigations, undermining recruitment and damaging staff morale. The report cited instances of midwives receiving death threats or being berated for working in 'failing' services. Stakeholders had told the HSSIB that clinicians had also become more risk-averse for fear of blame, a defensive approach that "drives the behaviour that compounds the harm women and families experience".
Yahoo
3 hours ago
- Yahoo
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. JENA, Germany, Aug. 21, 2025 /PRNewswire/ -- ZEISS Medical Technology today announced CE mark approval for CIRRUS® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician's workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder1 uses proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed element of a new CIRRUS software release, that also provides AI-enhanced OCTA image quality and multi-layer segmentation, helping to improve a practice's workflow efficiency and patient care. "At ZEISS, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience." "ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care," says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into ZEISS CIRRUS PathFinder." New research shows that physicians who leverage AI algorithms can be more effective than a practitioner alone. ZEISS CIRRUS with PathFinder delivers high-speed image capture with HD imaging detail 2, a wide field of view, and AI decision support, helping clinicians make more informed and efficient decisions. "With PathFinder AI Decision Support, our game-changing technology identifies OCT B-scans that may require additional review, raising our advanced diagnostic portfolio to a new level of patient care support," says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. Improved clinical decision support – Without requiring export and data analysis from third-party platforms, CIRRUS PathFinder's fully integrated AI decision support algorithm interprets data within the clinician's current workflow, allowing for the assessment of many hundreds of scans at once, in real time, upleveling the value of a clinician's time. During image acquisition, this AI-guided workflow tool flags areas that may require more detailed imaging and, during review, allows the user to focus on what matters – improving patient care. Improved OCTA image quality – New CIRRUS operating software provides AI-enhanced visualization of the vascular structure and B-scan averaging of the OCTA structural scans. Increased layer segmentation further enhances the user's diagnostic capability for even more efficient decision making. Enhanced connectivity and security – New cybersecurity features are designed to meet ever-evolving compliance and security needs. Additionally, the ZEISS CIRRUS platform ensures the seamless review of legacy OCT data combined with other diagnostic modalities to further enhance patient care. CIRRUS® PathFinder™ is available via license within the new CIRRUS software update, which includes an expanded Reference Database (RDB) that is triple the size of the previous RDB, cybersecurity enhancements, multi-layer segmentation, and improved OCTA visualization. The software update is available in select markets. For more information about CIRRUS PathFinder, go here. 1 ZEISS PathFinder works on all current ZEISS CIRRUS devices: 500, 5000, 6000, however RDB2 is for ZEISS CIRRUS 6000 data only.2 As it relates to the ZEISS CIRRUS 6000 only. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global CommunicationsZEISS OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: SOURCE Carl Zeiss Meditec AG Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
